文献速递类风湿关节炎

自身抗体对类风湿关节炎生物改善病情抗风湿药疗效的影响:随机对照试验的荟萃分析

The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该荟萃分析基于28项随机对照试验,比较自身抗体阳性与阴性类风湿关节炎患者使用生物改善病情抗风湿药的疗效。在未使用过传统合成改善病情抗风湿药和传统合成改善病情抗风湿药无效患者中,血清阳性与更好的疗效无关;仅在肿瘤坏死因子抑制剂无效患者中,6个月ACR20相对危险比值为2.28(1.31-3.95),有利于血清阳性患者。总体而言,无论人群、作用机制或具体药物,疗效在有无RF/ACPA患者中基本相当。

要点

  • 在未使用过csDMARD和csDMARD无效患者中,血清阳性与bDMARDs更好疗效无关。
  • 在TNFi无效患者中,6个月ACR20相对危险比值为2.28(1.31-3.95),有利于血清阳性患者。
  • 按作用机制或具体药物分析,RF阳性与RF阴性患者疗效相当。

核心结论

  • 无论患者人群、作用机制或具体药物,bDMARDs在RF/ACPA阳性和阴性患者中的疗效总体相当。

研究设计与样本

  • 检索EULAR RA管理特别工作组既往的系统文献综述以寻找符合条件的随机对照试验。
  • 纳入同时包含自身抗体阳性(≤80%总人群)和阴性RA患者、研究bDMARDs疗效的随机对照试验。
  • 共分析28项符合条件的随机对照试验数据,其中23项研究纳入三个亚组:6项为csDMARD初治患者,14项为csDMARD无效患者,3项为TNFi无效患者。
  • 对于比较bDMARD+csDMARD与csDMARD的试验,计算各治疗组中两组(RF+ vs RF-、ACPA+ vs ACPA-)疗效结局的相对危险度,再计算bDMARD组与非bDMARD组相对危险度的比值(RRR),采用随机效应荟萃分析合并效应。

主要发现

  • 在csDMARD初治和csDMARD无效患者中,血清阳性与bDMARDs更好疗效无关:合并6个月ACR20 RRR分别为1.02(0.88-1.18)和1.09(0.90-1.32)。
  • 在csDMARD初治和csDMARD无效患者中,其他结局也显示组间无差异。
  • 在TNFi无效患者中,基于三项试验,6个月ACR20 RRR为2.28(1.31-3.95),有利于血清阳性患者。
  • 在TNFi无效患者中,其他结局大多显示组间无显著差异。
  • 按作用机制分析,TNFi和非TNFi治疗中RF阳性与RF阴性患者疗效相当,各具体bDMARDs也相当。

关键数值与推荐

  • csDMARD初治患者合并6个月ACR20 RRR为1.02(0.88-1.18)。
  • csDMARD无效患者合并6个月ACR20 RRR为1.09(0.90-1.32)。
  • TNFi无效患者6个月ACR20 RRR为2.28(1.31-3.95)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy of bDMARDs in patients with RA with RF/ACPA compared with patients without these autoantibodies. METHODS: Previous systematic literature reviews performed by EULAR RA management task forces were searched for qualifying RCTs. RCTs investigating the efficacy of bDMARDs and including both autoantibody-positive (≤80% of total population) and -negative RA patients were eligible. For trials comparing bDMARD+csDMARD vs csDMARD, relative risks (RR) comparing two groups (RF+ vs RF-, ACPA+ vs ACPA-) were calculated for efficacy outcomes for each arm. Subsequently, relative risk ratios (RRRs) were computed, as the ratio of RR of the bDMARD-arm and the RR from the non-bDMARD-arm. Pooled effects were obtained with random effect meta-analyses. RESULTS: Data from 28 eligible RCTs were analysed, pooling 23 studies in three subgroups: six including csDMARD-naive patients, 14 csDMARD-IR and three TNFi-IR patients. In csDMARD-naive and csDMARD-IR patients, seropositivity was not associated with a better response to bDMARDs: pooled 6-month ACR20 RRRs 1.02 (0.88-1.18) and 1.09 (0.90-1.32), respectively. Other outcomes showed no difference between groups either. In TNFi-IR patients, based on three trials, the 6-month ACR20 RRR was 2.28 (1.31-3.95), favoring efficacy in seropositive patients. Other outcomes mostly showed no significant difference between the groups. Based on the mode of action, efficacy was comparable between RF-positive and RF-negative patients for both TNFi and non-TNFi treatment and also for the individual bDMARDs. CONCLUSION: The effect of bDMARDs is generally comparable in patients with and without RF/ACPA, regardless of the patient population, the mechanism of action or individual drug used.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Takase-Minegishi K, Böhringer S, Nam JL, et al. The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2025. PMID: 38366945. doi:10.1093/rheumatology/keae113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。